FI840219A - Human-humanhybridom foer neoplasmer. - Google Patents

Human-humanhybridom foer neoplasmer. Download PDF

Info

Publication number
FI840219A
FI840219A FI840219A FI840219A FI840219A FI 840219 A FI840219 A FI 840219A FI 840219 A FI840219 A FI 840219A FI 840219 A FI840219 A FI 840219A FI 840219 A FI840219 A FI 840219A
Authority
FI
Finland
Prior art keywords
human
neoplasmer
humanhybridom
foer
monoclonal antibodies
Prior art date
Application number
FI840219A
Other languages
English (en)
Other versions
FI86077B (fi
FI86077C (fi
FI840219A0 (fi
Inventor
Harold H Handley
Mark C Glassy
Hideaki Hagiwara
Yoshihide Hagiwara
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of FI840219A publication Critical patent/FI840219A/fi
Publication of FI840219A0 publication Critical patent/FI840219A0/fi
Publication of FI86077B publication Critical patent/FI86077B/fi
Application granted granted Critical
Publication of FI86077C publication Critical patent/FI86077C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI840219A 1982-05-21 1984-01-19 Monoklonala antikroppar och metod att producera dessa. FI86077C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
JP8484382 1982-05-21
US8300781 1983-05-20
PCT/US1983/000781 WO1983004313A1 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms

Publications (4)

Publication Number Publication Date
FI840219A true FI840219A (fi) 1984-01-19
FI840219A0 FI840219A0 (fi) 1984-01-19
FI86077B FI86077B (fi) 1992-03-31
FI86077C FI86077C (fi) 1992-07-10

Family

ID=13842073

Family Applications (1)

Application Number Title Priority Date Filing Date
FI840219A FI86077C (fi) 1982-05-21 1984-01-19 Monoklonala antikroppar och metod att producera dessa.

Country Status (13)

Country Link
EP (1) EP0109441B1 (fi)
JP (2) JPS58201994A (fi)
AT (1) ATE114189T1 (fi)
AU (1) AU560595B2 (fi)
CZ (1) CZ280677B6 (fi)
DE (1) DE3382764T2 (fi)
DK (1) DK164510C (fi)
FI (1) FI86077C (fi)
HU (1) HU190908B (fi)
IN (1) IN157982B (fi)
SK (1) SK356683A3 (fi)
WO (1) WO1983004313A1 (fi)
ZA (1) ZA833686B (fi)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
DE3483054D1 (de) * 1983-03-04 1990-10-04 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
GB2140030A (en) * 1983-04-08 1984-11-21 Kureha Chemical Ind Co Ltd Monoclonal antibody to human urinary bladder cancer
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
DK144485A (da) * 1984-03-30 1985-10-01 Syntex Inc Monoklonale antistoffer
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
EP0183876A1 (en) * 1984-11-27 1986-06-11 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibodies for endotoxin core and their use
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPH0655680B2 (ja) * 1985-10-26 1994-07-27 萩原 義秀 悪性腫瘍用ヒトモノクロナル抗体複合剤
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
JPH0767388B2 (ja) * 1986-01-13 1995-07-26 三菱化学株式会社 抗体産生細胞株の樹立方法
US5434076A (en) * 1989-12-18 1995-07-18 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
JPH04346792A (ja) * 1991-05-22 1992-12-02 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
DE69222909T2 (de) * 1991-08-16 1998-03-12 Toshiba Kawasaki Kk Monoklonaler Antikörper gegen ein Synaptophysin
DK1004315T3 (da) 1997-08-15 2008-07-21 Chugai Pharmaceutical Co Ltd Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus
CA2382587A1 (en) 1999-08-23 2001-03-01 Chugai Seiyaku Kabushiki Kaisha Hm1.24 antigen expression potentiators
SK4442002A3 (en) 1999-10-01 2003-04-01 Chugai Pharmaceutical Co Ltd Prevention and treatment of diseases associated with blood coagulation
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP2311489A3 (en) 2002-02-14 2013-08-21 Chugai Seiyaku Kabushiki Kaisha Formulation of antibody-containing solutions comprising a sugar as a stabilizer
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
HUE027134T2 (en) 2002-09-11 2016-10-28 Chugai Pharmaceutical Co Ltd Method for protein purification
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2348008T3 (es) 2003-06-18 2010-11-26 Chugai Seiyaku Kabushiki Kaisha Transportador de fucosa.
WO2005014818A1 (ja) 2003-08-08 2005-02-17 Perseus Proteomics Inc. 癌高発現遺伝子
EP2270152A1 (en) 2003-12-03 2011-01-05 Chugai Seiyaku Kabushiki Kaisha Expression system using mammalian beta-actin promoter
JPWO2005056605A1 (ja) 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
BRPI0506125B8 (pt) 2004-07-09 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo anti - glipicano 3, seu método de produção, polinucleotídeo, vetor e inibidor do crescimento de células
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
WO2006132363A1 (ja) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
JP5398987B2 (ja) 2005-11-14 2014-01-29 セルミド リミテッド 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
US20100080794A1 (en) 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
CA2654623C (en) 2006-06-08 2016-07-26 Chugai Seiyaku Kabushiki Kaisha An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
WO2007145227A1 (ja) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha 造血幹細胞増加促進剤
US20100150927A1 (en) 2006-07-13 2010-06-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2574625B1 (en) 2006-07-21 2015-02-25 HuBit genomix, Inc. Remedy for renal disease
ATE465179T1 (de) 2006-07-24 2010-05-15 Pasteur Institut Antikörper, antikörperfragmente und scfv die an posttranslational modifizierte neurotrophine binden
EP3111955B1 (en) 2006-08-14 2019-01-23 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
EP2083017A4 (en) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd ANTIBODIES HAVING INCREASED ADCC ACTIVITY AND METHOD FOR PRODUCING THE SAME
JP5687822B2 (ja) 2006-10-12 2015-03-25 中外製薬株式会社 抗ｅｒｅｇ抗体を用いる癌の診断および治療
CA2666559A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
JP5618172B2 (ja) 2007-01-05 2014-11-05 国立大学法人東京大学 抗ｐｒｇ−３抗体を用いる癌の診断および治療
JP5374360B2 (ja) 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
EP2175016A4 (en) 2007-06-25 2012-03-28 Forerunner Pharma Res Co Ltd ANTI-PROMININ-1 ANTIBODIES WITH ADCC ACTIVITY OR CDC ACTIVITY
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
AU2008308163B2 (en) 2007-10-02 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
CN102112492B (zh) 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
AU2008321835B2 (en) 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
ES2563483T3 (es) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
CN102124030B (zh) 2008-06-20 2015-06-17 国立大学法人冈山大学 抗氧化LDL/β2GPI复合物的抗体及其用途
MX2011006908A (es) 2008-12-26 2011-10-06 Univ Tokio Diagnosis y tratamiento del cancer utilizando el anticuerpo anti-lgr7.
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA2760642A1 (en) 2009-05-01 2010-11-04 The University Of Tokyo Anti-cadherin antibody
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
JP5752038B2 (ja) 2009-07-31 2015-07-22 愼 前田 癌の転移抑制剤
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
NO2535358T3 (fi) 2010-02-10 2018-05-19
JPWO2011105573A1 (ja) 2010-02-26 2013-06-20 株式会社 未来創薬研究所 抗ｉｃａｍ３抗体およびその用途
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
WO2012061120A1 (en) 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
US9328160B2 (en) 2010-10-29 2016-05-03 Perseus Proteomics Inc. Anti-CDH3 antibody having high internalization capacity
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
KR102398736B1 (ko) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
EP2876160B1 (en) 2012-07-06 2020-05-13 Kyoto Prefectural Public University Corporation Differentiation marker for and differentiation control for ocular cells
MX369550B (es) 2012-09-27 2019-11-12 Chugai Pharmaceutical Co Ltd Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
CN110475790A (zh) 2017-03-24 2019-11-19 全药工业株式会社 抗IgM/B细胞表面抗原双特异性抗体
KR20200074160A (ko) 2017-10-20 2020-06-24 가꼬우호우징 효고 이카다이가쿠 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
KR20210134705A (ko) 2019-02-28 2021-11-10 각코우호우진 쥰텐도 절단형의 변이형 Calreticulin에 결합하는 항체, 및 골수 증식성 종양의 진단, 예방 또는 치료약
JP7501876B2 (ja) 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
WO2020250940A1 (ja) 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
JPWO2021206078A1 (fi) 2020-04-06 2021-10-14
MX2023000854A (es) 2020-07-28 2023-02-15 Chugai Pharmaceutical Co Ltd Formulacion de jeringa precargada con aguja con protector de aguja que contiene nuevo anticuerpo modificado.
CA3192768A1 (en) 2020-08-27 2022-03-03 Juntendo Educational Foundation Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
TW202333787A (zh) 2021-12-01 2023-09-01 日商中外製藥股份有限公司 含抗體製劑的調製方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502090A (fi) * 1980-07-18 1982-11-25
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Also Published As

Publication number Publication date
FI86077B (fi) 1992-03-31
DK25084D0 (da) 1984-01-20
SK279249B6 (sk) 1998-08-05
EP0109441B1 (en) 1994-11-17
IN157982B (fi) 1986-08-09
DK25084A (da) 1984-01-20
FI86077C (fi) 1992-07-10
EP0109441A4 (en) 1986-09-22
DE3382764D1 (de) 1994-12-22
CZ280677B6 (cs) 1996-04-17
WO1983004313A1 (en) 1983-12-08
DE3382764T2 (de) 1995-03-16
ZA833686B (en) 1984-09-26
JPS58201994A (ja) 1983-11-25
ATE114189T1 (de) 1994-12-15
FI840219A0 (fi) 1984-01-19
EP0109441A1 (en) 1984-05-30
JPS60501359A (ja) 1985-08-22
SK356683A3 (en) 1998-08-05
AU1772983A (en) 1983-12-16
DK164510B (da) 1992-07-06
DK164510C (da) 1992-11-23
AU560595B2 (en) 1987-04-09
JPH0159878B2 (fi) 1989-12-20
CZ356683A3 (en) 1995-11-15
HU190908B (en) 1986-12-28

Similar Documents

Publication Publication Date Title
FI840219A (fi) Human-humanhybridom foer neoplasmer.
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
IT1160468B (it) Procedimento per la produzione di anticorpi monoclonali umani
PT86792A (pt) Monoclonal antibodies against melanoma-associated antigens hybrid cell lines producing these antibodies and use therefor
NO159883C (no) Monoklonalt antistoff.
NO159888C (no) Monoklonalt antistoff.
DK40885D0 (da) Monoklonalt antistof, fremgangsmaade og celle til fremstilling deraf,fremgangsmaade til fremstilling af cellen og farmaceutisk praeparat indeholdende det monoklonale antistof
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
NO159887C (no) Monoklonalt antistoff.
KR900018365A (ko) 모노클로날 항체 및 이의 용도
ES2064349T3 (es) Inmunoglobulinas humanas especificas del antigeno relacionado con el cancer e hibridomas humanos-humanos que pueden producir estas inmunoglobulinas humanas.
ES8502547A1 (es) Un metodo para determinar la presencia de una neoplasia.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
SE8401946D0 (sv) Antibody to human prostate cancer

Legal Events

Date Code Title Description
MA Patent expired

Owner name: THE REGENTS OF THE UNIVERSITY OF